Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Starting CDK inhibitors in the first-line setting did not improve OS. Is this true for every patient? Can it change practice?
SONIA Phase 3: HR+ HER2 – metastatic breast cancer
Patient populations that may benefit from first-line CDK inhibitors:
- Premenopausal patients
- Patients with high ctDNA levels
- Patients with more aggressive tumor biology
Final comment: The main issue in the first-line setting is the lack of OS benefit, with higher toxicity and cost.”
SONIA Trial Challenges Routine First-Line CDK4/6 Use in Advanced Breast Cancer
